Funded Startups in Basel-Stadt
Basel-Stadt's funded startup activity across these 34 rounds is concentrated almost entirely in life sciences — biotechnology accounts for 23 of the compan…
Basel-Stadt's funded startup activity across these 34 rounds is concentrated almost entirely in life sciences — biotechnology accounts for 23 of the companies, with health care adding six more. The largest disclosed round is Noema Pharma's $147M Series B in December 2024, followed by VectivBio's $125M Post-IPO Equity in October 2022, Bright Peak Therapeutics' $107M in June 2021, and Monte Rosa Therapeutics' $95M Series C in March 2021. Activity in 2024–2025 remains substantial: Granite Bio closed a $70M Series B in April 2025, and Nouscom raised $83M in March 2024.
Outside life sciences, the dataset includes Scailyte (AI, $2M Series A, December 2023), Lyfegen (financial services, $6M Series A, December 2024), and Typewise (apps, undisclosed Seed, September 2022 — based in Binningen rather than Basel proper). Kidemis, which raised $160K in agriculture and farming in April 2024, is the remaining non-pharma entry. Round sizes run from $30K Pre-Seed to nine-figure Series B, with at least four rounds carrying undisclosed amounts.
Most recent rounds
34 shownRelated listings
Frequently asked
What are the largest recent rounds among Basel-Stadt funded startups?
Noema Pharma raised $147M in a Series B in December 2024, and Granite Bio closed a $70M Series B in April 2025. Further back in the dataset, VectivBio raised $125M in a Post-IPO Equity round in October 2022 and Bright Peak Therapeutics raised $107M in June 2021.
Which sector dominates Basel-Stadt's funded startup activity?
Biotechnology accounts for 23 of the 34 companies in this dataset, with health care adding another six. The only companies outside life sciences are Scailyte (AI), Lyfegen (financial services), Typewise (apps), Kidemis (agriculture and farming), and BioTara (professional services).
Have any Basel-Stadt companies reached post-IPO or late-stage funding?
VectivBio raised $125M in a Post-IPO Equity round in October 2022. Monte Rosa Therapeutics closed a $95M Series C in March 2021. Series B rounds have remained active more recently, with Noema Pharma ($147M, December 2024), Granite Bio ($70M, April 2025), and Resistell AG ($9M, December 2022) among the examples.
What is the range of round sizes in this dataset?
Disclosed amounts span from $30K (DropGen, Pre-Seed, July 2025) to $147M (Noema Pharma, Series B, December 2024). At least four rounds — FimmCyte, Acthera Therapeutics, BioTara, and Typewise — list undisclosed amounts, so the effective range of visible data is wider.
Is there active early-stage dealflow signaling new company formation?
Three Pre-Seed rounds appear in the data: DropGen ($30K, July 2025), NXI Therapeutics ($4M, June 2024), and AERA Health ($4M, March 2023). Seed-stage deals include Engimmune Therapeutics ($16M, May 2022), Axom ($880K, June 2023), and KetoSwiss ($800K, August 2023).
Are all funded companies actually located in the city of Basel, or spread across the canton?
Nearly all companies list Basel as their city. Typewise, which raised an undisclosed Seed round in September 2022, is the one exception — it is based in Binningen, a municipality within the Basel-Stadt canton but outside Basel proper.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.